Search
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. … Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency.
Triprolidine
go.drugbank.com/drugs/DB00427ApprovedFirst generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSXylose
go.drugbank.com/drugs/DB09419ApprovedWithdrawnD-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe malabsorption. … The dextrorotary form of xylose, D-xylose, refers usually to the endogenously occurring form of the sugar in living things. The levorotary form, L-xylose, can refer to the form that is synthesized.
Belatacept
go.drugbank.com/drugs/DB06681ApprovedInvestigationalIt is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb.
Brinzolamide
go.drugbank.com/drugs/DB01194Approved[L35310,L35315] In Europe, it was also approved as a combination product with timolol in 2008.[L35320] … [A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.
Abametapir
go.drugbank.com/drugs/DB11932Approved[A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may
Ganaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment
Fluoxetine
go.drugbank.com/drugs/DB00472ApprovedInvestigationalVet approved[A181673] It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies … Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI).
Synonyms: (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine, (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamineInternational brands: Animex-OnRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalRaltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Categories: Antivirals used in combination for the treatment of HIV infections